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Summary Statement:  Dexamethasone intravitreal implant effectively reduced 
recalcitrant macular edema caused by retinal vein occlusion. Visual acuity initially 
improved with treatment. However at one year follow-up, it worsened compared to 
baseline in both phakic and pseudophakic eyes. 50% of phakic eyes underwent cataract 
surgery and 23% of eyes developed ocular hypertension.  
 
Abstract 
 
Purpose: To investigate efficacy of dexamethasone intravitreal implant (DEX) in treating 
refractory macular edema (ME) caused by retinal venous occlusion (RVO).  
Methods: Retrospective chart review.  
Results: 22 eyes with refractory ME caused by RVO were treated with a mean of 2.2 
DEX over 12 months. Patient had previously received a mean of 7 treatments (laser, 
bevacizumab, and/or triamcinolone) for ME present for at least 4 months duration (mean 
20.8 months 20.8 ± 17.6, range 4-72 months) prior to starting DEX. Mean baseline visual 
acuity (VA) was 20/91 and mean central subfield thickness (CSFT) was 506 μm. DEX 
improved mean BCVA to 20/75 and 20/66 at 7 week and 6 month follow-up, although it 
worsened to 20/132 at 12 months. Mean CSFT improved to 292, 352, and 356 μm at 7 
week, 6 month, and 12 month follow-up respectively. There was a statistically significant 
association between number of DEX treatments and CSFT  (p=3.28 x 10-9).  There was a 
statistically significant association between number of days followed and BCVA 
(p=0.006). 6 of 12 (50%) phakic patients developed visually significant cataract requiring 
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surgery. 5 of 22 (23%) patients developed ocular hypertension (intraocular pressure >30), 
and consequently did not undergo further treatment with DEX. 
Conclusions: DEX resulted in sustained anatomic reduction of RVO-associated 
refractory ME, although this did not translate into long term BCVA improvement in 
either phakic or pseudophakic patients, possibly related to chronic structural alterations in 
the retina despite reduction of edema. 
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Introduction 
 Vision loss from retinal vein occlusion (RVO) is frequently due to macular edema 
(ME).1 The pathogenesis of ME following RVO is related to a variety of factors, 
including hydrostatic effects from increased venous pressure, inflammatory cytokines, 
dysregulation of endothelial tight junctions, and increased amount of vascular 
permeability factors, including vascular endothelial growth factor (VEGF).2-4 Macular 
laser photocoagulation, intravitreal anti-VEGF agents, and intravitreal corticosteroids are 
commonly utilized treatments for macular edema caused by central retinal vein occlusion 
(CRVO) or branch retinal vein occlusion (BRVO). However, there are certain patients 
who develop refractory ME despite multiple treatments with the aforementioned 
modalities.   
 The dexamethasone (0.7 mg) intravitreal implant (DEX implant; OZURDEX, 
Allergan, Inc., Irvine, CA) was approved in 2009 to treat macular edema caused by 
retinal vein occlusion. It is contained in a solid bioerodable polymer for sustained-release, 
and can exert clinical effects for three to six months. The OZURDEX GENEVA study 
showed that both the 0.35g and 0.7 mg DEX implant groups were both superior to sham 
in preventing visual acuity loss, and improving the rapidity and incidence of visual acuity 
recovery in treatment-naïve eyes with ME secondary to CRVO or BRVO.5 The authors of 
this present study performed retrospective review of 0.7 mg DEX implant used to treat 
RVO-associated macular edema that had been refractory to multiple prior treatments.  
 
Methods 
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This retrospective, uncontrolled chart review studied patients diagnosed with 
refractory ME due to RVO, who were treated with their first DEX implant from March 
2010 through July 2015.  This project was reviewed by Indiana University’s IRB and 
considered exempt. Fluorescein angiography was performed on each patient on initial 
presentation to the clinic. Only patients diagnosed with CRVO or BRVO were included.  
Refractory ME was diagnosed if the patients experienced persistent ME of at least 
4 months duration despite at least 2 prior treatments, including any combination of 
macular laser photocoagulation, intravitreal triamcinolone acetonide, intravitreal 
bevacizumab, or intravitreal ranibizumab. In those patients who had undergone macular 
laser treatment, a grid pattern had been applied to areas with diffuse leakage, between 
500 and 3000 microns from the fovea; 532 nm laser was set to spot size of 50 microns at 
0.05 to 0.1 sec.  
Exclusion criteria included other causes of macular edema, such as diabetic 
retinopathy or neovascular age-related macular degeneration.  Patients were excluded if 
the baseline best corrected visual acuity (BCVA) was better than 20/40, the central 
subfield thickness (CSFT) on spectral domain optical coherence tomography (OCT) was 
less than 300 microns, or if the foveal avascular zone (FAZ) was enlarged to greater than 
1000 microns. A minimum of 6 months of follow-up was required to be eligible for the 
study.  
Patient charts were reviewed for eligibility, and data were extracted regarding the 
patient’s age, gender, previous interventions, and CSFT.  The BCVA, CSFT, intraocular 
pressure (IOP), lens status, treatment dates from the initial visit and follow-up visits were 
recorded.  Snellen visual acuity was converted to logarithm of minimal angle of 
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resolution (logMAR) for statistical analysis.  In cases of missing data points, the last 
observation was carried forward. Regression analysis was performed on the individual 
data to determine correlations between the independent variables of number of days 
follow-up or number of DEX implants and the dependent variables of logMAR VA or 
CSFT.  Mean values for logMAR VA and CSFT, as well as standard deviations and 
range, were calculated at each follow-up visit. 
On all visits, response to treatment was evaluated subjectively by Snellen visual 
acuity with best correction, and objectively by biomicroscopic examination and Zeiss 
Cirrus spectral domain OCT (Carl Zeiss Meditec, Jena, Germany).  In all cases, the use of 
DEX implant and its potential risks and benefits were discussed with the patients before 
signing an informed consent. DEX implant was injected 3.5-4mm posterior to the limbus 
under aseptic conditions. Subsequent injections were administered on an as needed basis 
for persistent macular edema on OCT affecting the foveal center. 
 
Results: 
The study included 22 eyes of 22 patients with ME caused by venous occlusion 
(10 patients with BRVO and 12 with CRVO). The mean age was 70 ± 17.6 years (range 
46- 86 years). There were 9 males and 13 females. 12 patients were phakic (55%) and 10 
were pseudophakic (45%) at the initiation of the study. All patients experienced ME for 
at least 4 months duration (mean 20.8 ± 17.6 months, range 4-72 months) prior to 
undergoing treatment with DEX implant (Table 1). 
Prior to treatment with DEX implant, this group of eyes received an average of 7 
prior treatments (22 eyes received 2-19 treatments including macular laser, intravitreal 
 7 
bevacizumab, ranibizumab, or triamcinolone acetonide). The mean washout period, in 
which no treatment was given prior to initial DEX implant, was 133 ± 97 days (median 
117 days, range 38-402 days). See Table 2. 
With respect to visual acuity, the mean BCVA prior to the initial DEX implant 
was 20/91 (logMAR 0.66 ± 0.25). This improved to 20/75 (logMAR 0.57 ± 0.32) at the 
first follow-up visit averaging 7 weeks later, and 20/66 (logMAR 0.52 ± 0.25) at the 6-
month follow-up. By the 1 year follow-up, mean BCVA worsened to 20/131 (logMAR 
0.82 ± 0.42), despite administration of a mean of 2.2 ± 0.85 DEX implants per patient 
(Table 3 and Figure 1). A statistically significant relationship was found between mean 
logMAR VA and number of days followed (p=0.006), but not for mean logMAR VA and 
number of DEX implants administered (p = 0.99).  
 Compared to BRVO patients, who started with better mean BCVA, CRVO 
patients experienced a greater initial improvement of mean BCVA. Ultimately, BRVO 
patients maintained an improved 6-month and 1 year mean BCVA, while the CRVO 
patients experienced loss of mean BCVA (Table 3 and Figure 1). 
With respect to macular edema as measured by OCT, prior to the initial DEX 
implant, CSFT for all patients averaged 506 ± 150 μm. At the first follow-up visit at an 
average of 7 weeks later, there was meaningful improvement to a mean of 292 ± 134 μm 
(42% reduction). Mean CSFT increased to 352 ± 152 μm and 356 ± 131 μm at 6 months 
(after mean 1.5 ± 0.51 DEX implants) and 12 months (after mean 2.2 ± 0.85 DEX 
implants) follow-up, respectively (Table 3 and Figure 2). A statistically significant 
relationship was found between mean CSFT and number of DEX implants administered 
(p=3.28 x 10-9), but not for mean CSFT and number of days followed (p=0.40).  
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BRVO patients exhibited a more favorable baseline mean CSFT compared to the 
CRVO group. Mean CSFT improved meaningfully for both BRVO and CRVO groups 
after the first DEX implants, but worsened on subsequent visits (Table 3 and Figure 2). 
We performed analysis to determine whether duration of ME prior to treatment with 
DEX correlated with treatment response. Patients with ME duration <12 months had a 
greater response to the first treatment, as mean logMAR improved by 0.23±0.07 (0.60 to 
0.37) and mean CSFT improved by 234±31 μm (539 μm to 305 μm). Patients with >12 
months duration of ME had a smaller improvement, as mean logMAR improved by 
0.08±0.07 (0.55 to 0.47) and mean CSFT improved by 199±52 μm, (479 μm to 280 μm). 
The difference in logMAR VA was statistically significant (p=0.05), while the difference 
in CSFT was not significant (p=0.27). 
With respect to intraocular pressure, mean IOP prior to the first DEX implant was 
16.7 ± 3.8, which increased to 21.2 ± 6 at the first follow-up visit (Table 3). 5 of 22 
patients (22.7%) were discontinued from additional treatment with DEX implant, due to 
development of ocular hypertension (IOP >30). These patients had a minimum of 2 DEX 
implants (similar to the mean of 2.2 DEX implants for all patients) and hence were 
considered in the final analysis. All 5 patients showed improved IOP (<21 mm Hg) after 
discontinuation of DEX implant and initiation of one topical IOP lowering agent.  
Regarding lens status, 6 of 12 initially phakic patients (50%) experienced cataract 
progression for which they underwent cataract surgery. This subset of patients was 
followed out to their most recent clinic visit (mean 970 days follow-up). Visually 
significant cataract was observed after a mean of 446 ± 36 days and 3.17 ± 0.75 DEX 
implants. The phakic patients showed mean baseline BCVA of 20/72 and one-year mean 
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BCVA of 20/105. The baseline pseudophakic patients exhibited worse mean baseline 
BCVA of 20/119 and one-year BCVA of 20/170 (Figure 3).  There were no cases of 
endophthalmitis, retinal detachment, or death throughout the study period. 
 
Conclusions 
 This study evaluated outcomes of repeated DEX implant injections to treat 
refractory ME caused by RVO. The results suggest that DEX implant is effective in 
reducing CSFT for a sustained period, but improvements in BCVA were transient. The 
greatest improvement in mean CSFT (42%) occurred after the first DEX implant,. The  
logMAR VA followed an undulating pattern, correlating with DEX treatment and its 
duration of action of approximately 3-4 months. The CRVO patients had a greater initial 
improvement in mean BCVA and mean CSFT, likely due to the fact that their baseline 
values were worse (with less potential for a ceiling effect), although ultimately only the 
BRVO subgroup maintained stable improvement in mean BCVA. 
There was a high incidence of visually significant cataract (particularly posterior 
subcapsular cataracts) that developed in phakic patients receiving repeated DEX implants 
and this can partially account for the deteriorating BCVA. However, baseline 
pseudophakic patients had a similar deterioration of BCVA at one year follow-up, 
suggesting that cataract formation cannot fully account for deterioration in vision. Other 
studies have suggested that patients with chronic edema fare poorly.  Even patients with 
macular edema for 6 months duration fare worse than those treated promptly; for 
example, in the pivotal Phase 3 randomized prospective clinical trial of 
ranibizumab for macular edema following CRVO (CRUISE), sham patients who crossed 
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over at 6 months to ranibizumab treatment, did not recover to the same degree at 12 
months, as those treated with ranibizumab from the start.6 
In the current study, the neuroretinal atrophy caused by chronic macular edema 
may be responsible for the worsening of vision in these patients despite reduction of 
macular edema.  It has been reported that patients with retinal vein occlusion with poor 
visual acuity (logMAR < 1.0) despite resolution of macular edema had OCT findings of 
inner retinal thinning (suggesting atrophy). The patients with relatively good visual acuity 
(logMAR <0.3) had the macular edema above the inner segments of the ellipsoid zone 
and had an intact ellipsoid zone more frequently after resolution of macular edema.7 Our 
analysis indicates that patients with duration of ME >12 months prior to treatment with 
DEX had statistically significant less improvement in logMAR after one treatment 
compared to those with <12 months duration, which may support these findings, as 
greater duration of ME would be more likely to cause chronic structural alterations in the 
retina despite reduction of edema. The difference in reduction of macular thickness was 
not statistically significant between these two groups. 
 These results show a more notable improvement in CSFT but less improvement in 
VA compared to results reported by Sharareh et al, who studied eyes with RVO-related 
macular edema refractory to multiple bevacizumab injections.8 Alshahrani et al reported 
that a single DEX implant caused a statistically significant improvement in both VA and 
CSFT in patients with refractory ME, which peaked at one and three months, and then 
lost significance by 6 months.9 Our results followed a similar pattern of significant 
improvement of mean BCVA and mean CSFT within the first 7 weeks, with diminished 
effects by 3 month follow-up and onward, despite repeated DEX implants.  
 11 
Limitations of this study include its uncontrolled retrospective nature without a 
standardized refraction protocol, lack of standardized regimen prior to initiating DEX 
treatment, and limited sample size. Furthermore, statistical analyses in retrospective 
studies are inherently flawed with hindsight bias, and consequently meant to be 
exploratory in nature for hypothesis generation.  Additionally, the washout period had a 
wide range of 38-402 days, which was likely due to poor follow up for selective patients 
that had failed to respond adequately to previous treatments. However consistent with 
prior studies, this study suggests that DEX may treat chronic RVO-related ME refractory 
to prior anti-VEGF treatment or laser photocoagulation, which is also consistent with the 
mechanism of action of corticosteroids. DEX implants reduce several pro-permeability 
proteins and inflammatory mediators, providing a multitargeted approach in treating 
RVO.10 Furthermore, in a recent large prospective trial of another corticosteroid, 
fluocinolone implant, for diabetic macular edema (DME), treatment was more effective 
in those eyes with chronic DME, and the authors speculated that chronic DME was 
driven by subclinical inflammation, compared to acute DME which is driven by VEGF.11 
It is biologically plausible that a similar phenomenon occurs in chronic refractory ME 
due to RVO. Nevertheless, this current study, along with the prior studies discussed 
herein, suggest that chronic edema is best avoided, given the guarded prognosis.  Clearly, 
further study of treatment regimens for refractory and/or chronic ME is warranted, given 
the visual disability caused. 
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Figure Captions: 
Figure 1. Mean logMAR visual acuity in relation to number of days of follow-up 
after first treatment in eyes treated with 0.7 mg intravitreal dexamethasone implant. 
Visual acuity followed a saw-toothed pattern that roughly correlated to the injection 
schedule, although at last follow-up it had significantly worsened compared to baseline. 
The BRVO group had relatively favorable outcomes compared to the CRVO group. 
Figure 2. Mean central subfield thickness (CSFT) in relation to number of days of 
follow-up after first treatment in eyes treated with 0.7 mg intravitreal dexamethasone 
implant. CSFT reduced drastically in the first 7 weeks, although it later plateaued on 
subsequent visits. 
Figure 3. Subgroup analysis of baseline phakic vs. pseudophakic eyes indicates 
that both groups had initial improvement of mean logMAR visual acuity with intravitreal 
dexamethasone treatment. However, after approximately 180 days follow-up, visual 
acuity began to worsen in both groups.   
Table 1. Baseline patient characteristics 
 
Gender 9/22 male, 11/22 female 
Mean age at diagnosis 70 ± 17.6 years (range 46-86 years) 
Central Retinal Vein Occlusion 12/22 patients 
Branch Retinal Vein Occlusion 10/22 patients 
Mean duration of macular edema 20.8 ± 17.6 months (range 4-72 months) 
Mean visual acuity 20/91 (logMAR 0.66 ± 0.25) 
Mean central subfield thickness 506 ± 150 μm (range 304-871 μm) 
Mean intraocular pressure 16.7 ± 3.8 mmHg (range 12-23) 
Lens status 12/22 phakic, 10/22 pseudophakic 
logMAR = logarithm of the minimum angle of resolution  
Table 2. Summary of mean number of treatments given for macular edema prior 0.7 
mg DEX implant. 
 
Tri = intravitreal triamcinolone acetonide; Bev = intravitreal bevacizumab; Ran = 
intravitreal ranibizumab; Bev-Tri = combination of bevacizumab and triamcinolone; SD 
= standard deviation; N/A = not applicable; * = prior to starting DEX implant 
 #Laser #Tri #Bev #Ran #Bev-Tri Total 
Mean 0.55 0.14 5.59 0.14 0.73 7 
SD 0.86 0.47 4.69 0.64 1.32 4.83 
Minimum 0 0 0 0 0 2 
Maximum 3 2 17 3 3 19 
# Eyes 
treated 
8 2 20 1 7  
Final 
treatment* 
5/22 eyes  0/22 eyes 14/22 eyes 0/22 eyes 3/22 eyes  
Mean 
washout 
period* 
135 days N/A 144 days N/A 81 days 133 days 
Table 3. Mean values of logMAR Visual Acuity, CSFT and IOP data in relation 
to number of days of treatment and number DEX implants.  
Total 
patients 
    Day  # DEX logMAR  CSFT(μm) IOP (mmHg) 
0.0 0.0 0.66±0.25  506±150 16.7±3.8 
52.1±25.6 1.0±0 0.57±0.32 292±134 21.0±6.0 
110.7±32.3 1.1±0.2 0.70±0.37 397±176 17.1±3.5 
179.5±40.1 1.5±0.5 0.52±0.25 352±152 19.1±5.9 
239.6±52.0 1.8±0.6 0.68±0.34 348±121 17.8±5.4 
294.0±79.6 2.0±0.7 0.43±0.29 349±152 17.9±6.9 
352.6±142.2 2.2±0.9 0.82±0.42 356±131 16.0±4.5 
CRVO only 
    Day  # DEX logMAR  CSFT(μm) IOP (mmHg) 
0.0 0.0 0.76±0.30 564±161 16.9±4.6 
52.8±34.3 1.0±0 0.62±0.36 312±168 21.6±6.9 
111.3±43.1 1.1±0.3 0.83±0.46 429±203 17.3±4.1 
182.6±48.3 1.6±0.5 0.58±0.32 375±191 20.2±7.6 
246.9±65.7 1.9±0.7 0.76±0.40 370±142 18.1±5.7 
316.3±89.8 2.3±0.5 0.66±0.35 382±194 19.8±8.6 
399.5±157.8 2.5±0.7 0.98±0.49 401±152 16.4±5.6 
BRVO only 
    Day  # DEX logMAR  CSFT(μm) IOP (mmHg) 
0.0 0.0 0.51±0.14 436±103 16.4±2.7 
51.2±9.5 1.0±0 0.51±0.28 267±75 20.2±4.9 
109.9±12.4 1.0±0 0.47±0.21 359±137 17.0±3.0 
175.7±29.3 1.4±0.5 0.43±0.14 324±86 17.8±2.7 
230.7±28.0 1.7±0.5 0.54±0.27 321±89 17.4±5.4 
267.2±58.8 1.8±0.8 0.39±0.19 309±67 15.6±3.3 
296.4±101.4 1.9±0.9 0.47±0.27 302±75 15.4±2.8 
319.5±126.4 1.9±0.9 0.40±0.20 358±118 15.3±2.9 
 
LogMAR = logarithm of the minimum angle of resolution; CSFT = central 
subfield thickness; IOP = intraocular pressure; mmHg = millimeters of mercury; DEX = 
Dexamethasone intravitreal implant; BRVO = Branch Retinal Vein Occlusion; CRVO = 
Central Retinal Vein Occlusion;   



